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The zebrafish (Danio rerio) has emerged as a powerful model to study vertebrate development
and disease. Its short generation time makes it amenable to genetic manipulation and analysis,
and its small size and high fecundity make it especially well suited for large-scale forward
genetic and chemical screens. Fast-developing zebrafish embryos are transparent, facilitating
live imaging of a variety of developmental processes in wild-type and mutant animals.
The zebrafish was originally chosen as a model with forward genetics in mind and has been
used successfully in countless genetic screens. However, it quickly became a priority to be able
to disrupt the function of specific genes in a targeted way. In the early 2000s, in the absence of
tools for efficient targeted mutagenesis, morpholino (MO) antisense oligomers became the
tool of choice for gene knockdown in a range of models including Xenopus, zebrafish, sea
urchin, and chick [1, 2]. MOs are chemically synthesized oligomers that are typically injected
into embryos at the 1-cell stage, bind complementary target mRNAs, and prevent their transla-
tion or splicing. They are similar to small interfering RNAs (siRNAs) and short hairpin RNAs
(shRNAs) in that they interfere with the function of a gene without altering its sequence.
Based on their ability to phenocopy well-characterized mutants, MOs were rapidly adopted
by zebrafish researchers to disrupt the function of genes that had not been uncovered by for-
ward genetic screens. However, concerns soon arose about the off-target effects of MOs, moti-
vating leading scientists in the zebrafish and Xenopus fields to publish a set of guidelines
including controls and rescue experiments that, if followed carefully, would help distinguish
specific phenotypes from off-target effects [3]. Since that time, the number of zebrafish lines
carrying mutations in genes of interest has grown, at first gradually, from ongoing forward
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genetic screens and TILLING efforts, and then exponentially, with the advent of zinc finger
nucleases, TALENs, and CRISPRs. The ease of generating mutants now allows the reevaluation
of MO-induced versus mutant phenotypes and has led to the surprising finding that, even with
the careful application of the Eisen and Smith guidelines [3], MO-induced phenotypes can be
different and often more severe than those of the corresponding mutants.
This brief document provides an updated set of guidelines regarding the use of MOs in zeb-
rafish that we anticipate will be of value for experimentalists as well as journal and grant
reviewers, and decision makers. These general guidelines build upon those by Eisen and Smith
[3] taking into account new developments and findings in the field, namely, the following:
1. In addition to the wealth of available ENU and insertional mutant alleles in zebrafish,
TALEN and CRISPR/Cas9 tools have made genome editing widely possible;
2. MO-induced phenotypes are often more severe than those of the corresponding mutants,
which could be due to the following:
a. phenotypic rescue of zygotic mutants by maternally provided wild-type mRNAs, the
translation of which can be blocked by MOs,
b. off-target effects of the MO (e.g., Kok et al. 2015 [4]),
c. the hypomorphic nature of the mutant allele analyzed, or
d. genetic compensation in mutant but not MO-injected animals (also known as mor-
phants) (e.g., Rossi et al. 2015 [5]).
MOs are like any other knockdown reagents; their use should thus be evaluated by journal/
grant reviewers and decision makers accordingly (i.e., on a comparable footing to siRNAs, for
example). However, antisense approaches are not a form of reverse genetics.
As mentioned above, the advent of TALEN and CRISPR/Cas9 tools has now made it rou-
tine to generate stable mutant lines and hence to use reverse genetics to study gene function in
zebrafish. Additionally, mutant alleles for many genes are now readily available through zebra-
fish community resource centers. Thus, MOs should be used alongside mutant(s) for the cor-
responding gene. When used in line with the following guidelines, MO-based studies can
complement mutant studies, providing an additional and useful approach to our understand-
ing of gene function.
The possibility of obtaining or generating mutants allows the morphant and mutant pheno-
types to be directly compared (Fig 1A). If they are the same, and if the MO experiments satisfy
the criteria initially laid out by Eisen and Smith [3] (Fig 1B and see below), then the morphant
can be considered an acceptable alternative to the mutant for follow-up studies concerning
that specific phenotype (e.g., generating a partial loss-of-function series by using progressively
lower doses of MO, or generating a population of embryos knocked down for a specific gene
product, Fig 1C). (Note that caution should be exercised when conducting molecular analyses
[e.g., transcriptome or proteome], as it is likely that MOs cause additional effects besides
blocking the translation/splicing of target mRNAs.) If a new phenotype is analyzed or the
same phenotype examined using a different assay, the mutants and morphants should first be
compared directly before considering the morpholino validated.
If a morphant phenotype is more severe than, or different from, a mutant phenotype, deci-
sive experiments can be performed to distinguish between the 4 possible reasons listed above:
(i) To test the possibility that the morphant phenotype is more severe because the zygotic
mutant is rescued by maternally provided wild-type mRNAs, the morphant phenotype can be
compared to the maternal-zygotic (MZ) mutant phenotype (Fig 1D). (Note that, for maternally
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expressed genes with essential zygotic functions, the generation of viable and fertile homozy-
gous mutant females is not possible. In such cases, wild-type females with homozygous mutant
germ lines can be generated by germ line replacement [6]. If, however, the gene of interest has
an essential cell-autonomous function in the development of the germ line, germ line replace-
ment is not possible and thus one will not be able to directly compare the morphant and MZ
mutant phenotypes; in such cases, given the current technology, gene function can only be
studied using nongenetic tools (Fig 1H).) (ii) A decisive approach to determine the optimal
sequence and dose of a MO that does not cause off-target effects is to inject the MO into
embryos whose genome (and whose mother’s genome, for maternally expressed genes) has
been edited so as to eliminate the MO-binding site or to eliminate the function of the target
gene (Fig 1E). (Note that demonstrating that an allele is a null can be challenging either geneti-
cally, as very few deficiency alleles are available in zebrafish, or biochemically, as antibodies
recognizing various epitopes along the protein are usually not available. Whole-gene deletions
might also affect additional genetic elements present in introns, and recent studies have
revealed a surprising ability of the genome to circumvent putatively deleterious nonsense and
frameshift mutations [7, 8, 9]. Care should thus be taken when designing targeting tools to
avoid these pitfalls.) Any additional phenotype caused by the MO beyond that of the mutant is
Fig 1. Flowchart for zebrafish researchers interested in using morpholinos (MOs) to study the function of gene x.
https://doi.org/10.1371/journal.pgen.1007000.g001
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by definition an off-target effect and invalidates the use of the MO (Fig 1F). If, however, a MO
phenotype that is detected in wild-type embryos disappears or is strongly suppressed upon
injection into embryos homozygous for a null allele, such an observation suggests that genetic
compensation may be occurring in the mutant (Fig 1G).
In summary, a MO should be validated by comparison to a mutant, and if there is a discrep-
ancy, by injection into embryos homozygous for a null allele or an allele lacking the MO-bind-
ing site. Although the control of injecting the MO into a mutant provides the most definitive
evidence for MO specificity, we suggest the following additional guidelines for MO use, espe-
cially for situations in which a mutant cannot be generated.
• Multiple MOs (ATG and splice blocking), or MOs and another approach (e.g., CRISPR-
induced mutagenesis or CRISPR interference [CRISPRi]) should be used to target individual
genes, and their efficiency should be assessed whenever possible (e.g., using antibodies,
RT-PCR, qPCR) to minimize the amount of MO injected.
• Rescue experiments should be attempted for the approaches listed above (e.g., by injection of
mRNA or DNA lacking the MO-binding site in the case of MO studies), and if rescue is suc-
cessful, control experiments should be conducted (e.g., using mutant RNA or DNA, i.e.,
RNA or DNA that does not encode a functional gene product).
• An injection control MO (standard negative control MO, 5-base mismatch MO, or a suitable
alternative MO) should be used to account for developmental delay. Such MOs cannot serve
as controls for the specificity of the experimental MO.
• The approach of validating ATG MOs by assessing their ability to suppress the expression of
a co-injected target mRNA-GFP fusion is of little value as we now know that suppression of
GFP expression is generally observed and it does not test the effect of the MO on the endoge-
nous RNA. This control is no longer recommended
• Essential routine procedures include a dose response curve (extra caution should be exer-
cised when one has to inject more than 5 ng of a MO to cause a phenotype [10]), the exami-
nation of statistically meaningful numbers of control and experimental animals, extensive
documentation of the penetrance and expressivity of all phenotypes, and the use of blinding
strategies whenever possible.
Finally, a word of caution that previous publication of MOs is not a guarantee of their fidel-
ity, particularly if a new phenotype is being described. These reagents should be critically eval-
uated to ascertain that they were properly characterized; ideally, key controls such as dose
response curves and rescue experiments should be repeated when using these tools, and such
data included in the manuscript.
Of course, there will be exceptions when the full set of guidelines cannot be followed. In
these cases, appropriate caveats should be considered and included in the text that describes
the use of the MOs, the results obtained, and their interpretation.
In conclusion, we hope that these brief and mostly conceptual guidelines will assist scien-
tists working with zebrafish as well as those assessing manuscripts and grant proposals based
on experiments using zebrafish. In addition, these guidelines may become helpful for other
communities using antisense reagents to study gene function.
References
1. Heasman J, Kofron M, Wylie C. Beta-catenin signaling activity dissected in the early Xenopus embryo:
a novel antisense approach. Dev Biol. 2000; 222:124–34. https://doi.org/10.1006/dbio.2000.9720
PMID: 10885751.
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007000 October 19, 2017 4 / 5
2. Nasevicius A, Ekker SC. Effective targeted gene ’knockdown’ in zebrafish. Nat Genet. 2000; 26:216–
220. https://doi.org/10.1038/79951 PMID: 11017081.
3. Eisen JS, Smith JC. Controlling morpholino experiments: don’t stop making antisense. Development.
2008; 135:1735–1743. https://doi.org/10.1242/dev.001115 PMID: 18403413.
4. Kok FO, Shin M, Ni C, Gupta A, Grosse AS, van Impel A, et al. Reverse Genetic Screening Reveals
Poor Correlation between Morpholino-Induced and Mutant Phenotypes in Zebrafish. Dev Cell. 2015;
32:97–108. https://doi.org/10.1016/j.devcel.2014.11.018 PMID: 25533206.
5. Rossi A, Kontarakis Z, Gerri C, Nolte H, Ho¨lper S, Kru¨ger M, et al. Genetic compensation induced by
deleterious mutations but not gene knockdowns. Nature. 2015; 524:230–3. https://doi.org/10.1038/
nature14580 PMID: 26168398.
6. Ciruna B, Weidinger G, Knaut H, Thisse B, Thisse C, Raz E, et al. Production of maternal-zygotic
mutant zebrafish by germ-line replacement. Proc Natl Acad Sci U S A. 2002; 99:14919–14924. https://
doi.org/10.1073/pnas.222459999 PMID: 12397179.
7. Jagannathan S, Bradley RK. Translational plasticity facilitates the accumulation of nonsense genetic
variants in the human population. Genome Research. 2016; 26:1639–1650. https://doi.org/10.1101/gr.
205070.116 PMID: 27646533.
8. Lalonde S, Stone OA, Lessard S, Lavertu A, Desjardins J, Beaudoin M, et al. Frameshift indels intro-
duced by genome editing can lead to in-frame exon skipping. PLoS ONE. 2017; 12:e0178700. https://
doi.org/10.1371/journal.pone.0178700 PMID: 28570605.
9. Prykhozhij SV, Steele SL, Razaghi B, Berman JN. A rapid and effective method for screening, sequenc-
ing and reporter verification of engineered frameshift mutations in zebrafish. Disease Models & Mecha-
nisms. 2017; 10:811–822. https://doi.org/10.1242/dmm.026765 PMID: 28280001.
10. Schulte-Merker S, Stainier DY. Out with the old, in with the new: reassessing morpholino knockdowns
in light of genome editing technology. Development. 2014; 141:3103–4. https://doi.org/10.1242/dev.
112003 PMID: 25100652.
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007000 October 19, 2017 5 / 5
